Joan-Carles Arce

Chief Scientific Officer

Joan-Carles Arce is responsible for Ferring US drug development activities, regulatory affairs, pharmacovigilance and medical affairs.

Joan-Carles has more than 25 years of experience in the pharmaceutical industry. Prior to joining Ferring US in 2016, he was Vice President of Science & Medicine for Reproductive Health and Vice President of Global Clinical Development Support at the Ferring International PharmaScience Center in Denmark. Before joining Ferring in 2002, he worked for Novo Nordisk in Denmark, and earlier for Merck KGaA-Lipha in France. Joan-Carles has authored more than 100 publications and has presented at numerous scientific meetings and industry conferences.

Joan-Carles received his M.D. from the Autonomous University of Barcelona Medical School in Spain, and a Ph.D from the Free University Faculty of Medicine and Pharmacy in Brussels, Belgium. He conducted a postdoctoral fellowship at the University of Connecticut Health Center.

This site contains material about Ferring Pharmaceuticals Inc. (hereinafter "Ferring") and its various products that may be of interest to Ferring's employees and customers, as well as to members of the health care community and the general public. Please feel free to browse this web site. Your access and use of the information contained herein is subject to the following terms and conditions and all applicable laws. By accessing and browsing this web site, you accept, without limitation or qualification, these terms and conditions and acknowledge that they supersede any other agreement between you and Ferring.

All information on this site is intended for US audiences only.

CERVIDIL, CLENPIQ, ENDOMETRIN, EUFLEXXA, FIRMAGON, MENOPUR, NOCDURNA, NOVAREL, and ZOMACTON are registered trademarks of Ferring B.V. INVOCELL is a registered trademark of INVO BioScience.

©2008-2019 Ferring Pharmaceuticals.  US--1900006